These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
295 related articles for article (PubMed ID: 19400959)
1. Using molecular similarity to highlight the challenges of routine immunoassay-based drug of abuse/toxicology screening in emergency medicine. Krasowski MD; Pizon AF; Siam MG; Giannoutsos S; Iyer M; Ekins S BMC Emerg Med; 2009 Apr; 9():5. PubMed ID: 19400959 [TBL] [Abstract][Full Text] [Related]
2. Accidental intoxications in toddlers: lack of cross-reactivity of vilazodone and its urinary metabolite M17 with drug of abuse screening immunoassays. Martinez-Brokaw CD; Radke JB; Pierce JG; Ehlers A; Ekins S; Wood KE; Maakestad J; Rymer JA; Tamama K; Krasowski MD BMC Clin Pathol; 2019; 19():2. PubMed ID: 30820187 [TBL] [Abstract][Full Text] [Related]
3. Chemoinformatic methods for predicting interference in drug of abuse/toxicology immunoassays. Krasowski MD; Siam MG; Iyer M; Pizon AF; Giannoutsos S; Ekins S Clin Chem; 2009 Jun; 55(6):1203-13. PubMed ID: 19342505 [TBL] [Abstract][Full Text] [Related]
4. Lack of Detection of New Amphetamine-Like Drugs Using Conventional Urinary Immunoassays. Begeman A; Franssen EJF Ther Drug Monit; 2018 Feb; 40(1):135-139. PubMed ID: 29194289 [TBL] [Abstract][Full Text] [Related]
5. Optimization of cloned enzyme donor immunoassay cut-offs for drugs of abuse in post-mortem whole blood. Pelletti G; Rossi F; Garagnani M; Barone R; Roffi R; Fais P; Pelotti S Forensic Sci Int; 2020 Jul; 312():110291. PubMed ID: 32353744 [TBL] [Abstract][Full Text] [Related]
6. Cross-reactivity studies and predictive modeling of "Bath Salts" and other amphetamine-type stimulants with amphetamine screening immunoassays. Petrie M; Lynch KL; Ekins S; Chang JS; Goetz RJ; Wu AH; Krasowski MD Clin Toxicol (Phila); 2013 Feb; 51(2):83-91. PubMed ID: 23387345 [TBL] [Abstract][Full Text] [Related]
7. Optimization of cloned enzyme donor immunoassay cut-offs for drugs of abuse in whole blood of drivers involved in road accidents. Pelletti G; Garagnani M; Rossi F; Roffi R; Barone R; Pelotti S Forensic Sci Int; 2019 Jan; 294():27-33. PubMed ID: 30447484 [TBL] [Abstract][Full Text] [Related]
8. Protocol for accuracy of point of care (POC) or in-office urine drug testing (immunoassay) in chronic pain patients: a prospective analysis of immunoassay and liquid chromatography tandem mass spectometry (LC/MS/MS). Manchikanti L; Malla Y; Wargo BW; Cash KA; Pampati V; Damron KS; McManus CD; Brandon DE Pain Physician; 2010; 13(1):E1-E22. PubMed ID: 20119473 [TBL] [Abstract][Full Text] [Related]
9. False-positive interferences of common urine drug screen immunoassays: a review. Saitman A; Park HD; Fitzgerald RL J Anal Toxicol; 2014 Sep; 38(7):387-96. PubMed ID: 24986836 [TBL] [Abstract][Full Text] [Related]
10. Optimization and validation of CEDIA drugs of abuse immunoassay tests in serum on Hitachi 912. Kirschbaum KM; Musshoff F; Schmithausen R; Stockhausen S; Madea B Forensic Sci Int; 2011 Oct; 212(1-3):252-5. PubMed ID: 21775079 [TBL] [Abstract][Full Text] [Related]
11. Evaluation and applicability of Alere iCup DX 14 for rapid postmortem urine drug screening at autopsy. Towler S; Concheiro M; Pearring S; Rodda LN J Forensic Sci; 2021 Jan; 66(1):375-382. PubMed ID: 33022072 [TBL] [Abstract][Full Text] [Related]
12. Signify ER Drug Screen Test evaluation: comparison to Triage Drug of Abuse Panel plus tricyclic antidepressants. Phillips JE; Bogema S; Fu P; Furmaga W; Wu AH; Zic V; Hammett-Stabler C Clin Chim Acta; 2003 Feb; 328(1-2):31-8. PubMed ID: 12559596 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of the on-site immunoassay drug-screening device Triage-TOX in routine forensic autopsy. Tominaga M; Michiue T; Maeda H Leg Med (Tokyo); 2015 Nov; 17(6):499-502. PubMed ID: 26593997 [TBL] [Abstract][Full Text] [Related]
14. Assessment of urine drug screen utility at autopsy to predict laboratory postmortem blood toxicology. Arndt C; Huestis MA; Jarvis HC; Gray TR J Forensic Sci; 2024 Sep; 69(5):1815-1825. PubMed ID: 38898613 [TBL] [Abstract][Full Text] [Related]
15. Clinical issues associated with urine testing of substances of abuse. Eskridge KD; Guthrie SK Pharmacotherapy; 1997; 17(3):497-510. PubMed ID: 9165553 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of immunochemical drug screenings of whole blood samples. A retrospective optimization of cutoff levels after confirmation-analysis on GC-MS and HPLC-DAD. Kroener L; Musshoff F; Madea B J Anal Toxicol; 2003; 27(4):205-12. PubMed ID: 12820742 [TBL] [Abstract][Full Text] [Related]
17. Hair analysis by immunological methods from the beginning to 2000. Spiehler V Forensic Sci Int; 2000 Jan; 107(1-3):249-59. PubMed ID: 10689577 [TBL] [Abstract][Full Text] [Related]
18. Analytic performance of immunoassays for drugs of abuse below established cutoff values. Luzzi VI; Saunders AN; Koenig JW; Turk J; Lo SF; Garg UC; Dietzen DJ Clin Chem; 2004 Apr; 50(4):717-22. PubMed ID: 14764642 [TBL] [Abstract][Full Text] [Related]
19. Comparison of several immunoassays used in drugs of abuse screening: Assessment against gold standard methods and calculation of measurement uncertainty. Mina A J Pharmacol Toxicol Methods; 2020; 101():106649. PubMed ID: 31730939 [TBL] [Abstract][Full Text] [Related]
20. A Difficult Challenge for the Clinical Laboratory: Accessing and Interpreting Manufacturer Cross-Reactivity Data for Immunoassays Used in Urine Drug Testing. Reschly-Krasowski JM; Krasowski MD Acad Pathol; 2018; 5():2374289518811797. PubMed ID: 30480089 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]